Arcutis Biotherapeutics Inc (NASDAQ: ARQT) on Friday, soared 5.69% from the previous trading day, before settling in for the closing price of $15.98. Within the past 52 weeks, ARQT’s price has moved between $8.03 and $17.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -0.98%. The company achieved an average annual earnings per share of 60.34%. With a float of $104.50 million, this company’s outstanding shares have now reached $119.80 million.
Let’s determine the extent of company efficiency that accounts for 342 employees. In terms of profitability, gross margin is 89.1%, operating margin of -32.58%, and the pretax margin is -35.04%.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcutis Biotherapeutics Inc is 11.95%, while institutional ownership is 98.75%. The most recent insider transaction that took place on Aug 08 ’25, was worth 53,988. In this transaction an insider of this company sold 3,847 shares at a rate of $14.03, taking the stock ownership to the 108,999 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Former Officer proposed sale 41,979 for $14.58, making the entire transaction worth $611,936.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.33 earnings per share (EPS) for the period topping the consensus outlook (set at -0.43) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.34% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Arcutis Biotherapeutics Inc (ARQT) is currently performing well based on its current performance indicators. A quick ratio of 3.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.74, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 2.1 million, which is a drop from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 85.32%.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 85.40%, which indicates a significant decrease from 99.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.92 in the past 14 days, which was higher than the 0.86 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.49, while its 200-day Moving Average is $13.63. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $17.17. Second resistance stands at $17.46. The third major resistance level sits at $18.00. If the price goes on to break the first support level at $16.34, it is likely to go to the next support level at $15.80. Now, if the price goes above the second support level, the third support stands at $15.51.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
Market capitalization of the company is 2.03 billion based on 119,905K outstanding shares. Right now, sales total 196,540 K and income totals -140,040 K. The company made 81,500 K in profit during its latest quarter, and -15,890 K in sales during its previous quarter.
